synovial sarcoma
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
August 2, 2024Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
